M
MERUS BV
NASDAQ: MRUS (Merus N.V.)
Last update: 19 hours ago41.85
-0.24 (-0.57%)
| Previous Close | 42.09 |
| Open | 42.39 |
| Volume | 723,520 |
| Avg. Volume (3M) | 537,536 |
| Market Cap | 2,865,205,504 |
| Price / Sales | 73.33 |
| Price / Book | 4.17 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Operating Margin (TTM) | -613.59% |
| Diluted EPS (TTM) | -4.03 |
| Quarterly Revenue Growth (YOY) | 6.70% |
| Total Debt/Equity (MRQ) | 1.57% |
| Current Ratio (MRQ) | 8.32 |
| Operating Cash Flow (TTM) | -155.52 M |
| Levered Free Cash Flow (TTM) | -109.10 M |
| Return on Assets (TTM) | -21.59% |
| Return on Equity (TTM) | -44.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Merus N.V. | Bullish | Bullish |
AIStockmoo Score
2.3
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 2.25 |
|
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 2.03% |
| % Held by Institutions | 105.66% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Commodore Capital Lp | 30 Sep 2024 | 3,350,000 |
| Lynx1 Capital Management Lp | 30 Sep 2024 | 1,793,866 |
| Holocene Advisors, Lp | 30 Sep 2024 | 1,637,988 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 111.00 (Guggenheim, 165.23%) | Buy |
| Median | 85.00 (103.11%) | |
| Low | 72.00 (UBS, 72.04%) | Buy |
| Average | 87.17 (108.29%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 45.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 09 Dec 2024 | 97.00 (131.78%) | Buy | 43.74 |
| Needham | 09 Dec 2024 | 85.00 (103.11%) | Buy | 43.74 |
| 05 Dec 2024 | 85.00 (103.11%) | Buy | 43.86 | |
| Guggenheim | 05 Dec 2024 | 111.00 (165.23%) | Buy | 43.86 |
| 03 Dec 2024 | 109.00 (160.45%) | Buy | 46.21 | |
| HC Wainwright & Co. | 05 Dec 2024 | 85.00 (103.11%) | Buy | 43.86 |
| 02 Dec 2024 | 85.00 (103.11%) | Buy | 48.53 | |
| Goldman Sachs | 21 Nov 2024 | 73.00 (74.43%) | Buy | 44.36 |
| UBS | 24 Oct 2024 | 72.00 (72.04%) | Buy | 52.30 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |